| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Gastrointestinal Stromal Tumors | 93 | 2022 | 616 | 11.840 |
Why?
|
| Sarcoma | 74 | 2024 | 1804 | 8.740 |
Why?
|
| Piperazines | 73 | 2021 | 2552 | 5.550 |
Why?
|
| Pyrimidines | 79 | 2021 | 3046 | 5.510 |
Why?
|
| Antineoplastic Agents, Alkylating | 26 | 2021 | 614 | 4.950 |
Why?
|
| Gastrointestinal Neoplasms | 46 | 2022 | 957 | 4.070 |
Why?
|
| Proto-Oncogene Proteins c-kit | 60 | 2021 | 723 | 4.030 |
Why?
|
| Dioxoles | 18 | 2017 | 96 | 3.990 |
Why?
|
| Pyrroles | 35 | 2016 | 1123 | 3.980 |
Why?
|
| Benzamides | 76 | 2022 | 1377 | 3.870 |
Why?
|
| Indoles | 35 | 2016 | 1835 | 3.480 |
Why?
|
| Liposarcoma | 15 | 2019 | 289 | 3.400 |
Why?
|
| Leiomyosarcoma | 19 | 2022 | 426 | 3.320 |
Why?
|
| Antineoplastic Agents | 114 | 2021 | 13658 | 3.250 |
Why?
|
| Tetrahydroisoquinolines | 18 | 2017 | 81 | 3.220 |
Why?
|
| Soft Tissue Neoplasms | 27 | 2023 | 1164 | 2.370 |
Why?
|
| Protein Kinase Inhibitors | 49 | 2023 | 5694 | 2.360 |
Why?
|
| Dacarbazine | 8 | 2021 | 552 | 2.270 |
Why?
|
| Phenylurea Compounds | 14 | 2019 | 531 | 2.100 |
Why?
|
| Drug Resistance, Neoplasm | 39 | 2021 | 5335 | 1.620 |
Why?
|
| Doxorubicin | 16 | 2024 | 2234 | 1.590 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 47 | 2024 | 11873 | 1.420 |
Why?
|
| Disease-Free Survival | 55 | 2018 | 6843 | 1.360 |
Why?
|
| Bone Neoplasms | 13 | 2023 | 2564 | 1.330 |
Why?
|
| Protein-Tyrosine Kinases | 25 | 2022 | 2428 | 1.270 |
Why?
|
| Antibiotics, Antineoplastic | 7 | 2014 | 681 | 1.180 |
Why?
|
| Pyridines | 17 | 2019 | 2893 | 1.150 |
Why?
|
| Neoplasms | 49 | 2024 | 22365 | 1.130 |
Why?
|
| Erythropoietin | 14 | 2005 | 718 | 1.110 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 18 | 2018 | 367 | 1.080 |
Why?
|
| Isoquinolines | 8 | 2021 | 354 | 1.070 |
Why?
|
| Drug Administration Schedule | 29 | 2021 | 4857 | 1.010 |
Why?
|
| Angiogenesis Inhibitors | 10 | 2019 | 2055 | 0.950 |
Why?
|
| Sarcoma, Synovial | 7 | 2024 | 156 | 0.930 |
Why?
|
| Anemia | 13 | 2024 | 1514 | 0.830 |
Why?
|
| Maximum Tolerated Dose | 10 | 2024 | 897 | 0.830 |
Why?
|
| Thiazolidinediones | 8 | 2012 | 460 | 0.810 |
Why?
|
| Treatment Outcome | 89 | 2024 | 65364 | 0.800 |
Why?
|
| Tropomyosin | 3 | 2023 | 106 | 0.800 |
Why?
|
| TOR Serine-Threonine Kinases | 11 | 2014 | 2061 | 0.790 |
Why?
|
| Kaplan-Meier Estimate | 24 | 2020 | 6517 | 0.750 |
Why?
|
| Indazoles | 7 | 2022 | 306 | 0.720 |
Why?
|
| Ifosfamide | 8 | 2024 | 233 | 0.720 |
Why?
|
| Sirolimus | 7 | 2013 | 1538 | 0.720 |
Why?
|
| Adult | 156 | 2024 | 223583 | 0.710 |
Why?
|
| Humans | 337 | 2024 | 767991 | 0.710 |
Why?
|
| Middle Aged | 165 | 2024 | 223422 | 0.700 |
Why?
|
| Aged | 135 | 2024 | 171446 | 0.700 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 10 | 2021 | 1621 | 0.670 |
Why?
|
| Anthracyclines | 4 | 2020 | 286 | 0.660 |
Why?
|
| Ketones | 2 | 2017 | 183 | 0.650 |
Why?
|
| Furans | 2 | 2017 | 199 | 0.640 |
Why?
|
| Uterine Neoplasms | 6 | 2017 | 1424 | 0.630 |
Why?
|
| Thrombocytopenia | 8 | 2024 | 1179 | 0.630 |
Why?
|
| Medical Oncology | 10 | 2021 | 2341 | 0.620 |
Why?
|
| Neutropenia | 13 | 2019 | 892 | 0.600 |
Why?
|
| Pyrazoles | 6 | 2023 | 2028 | 0.600 |
Why?
|
| Neoplasm Recurrence, Local | 18 | 2021 | 9412 | 0.580 |
Why?
|
| Hematopoietic Cell Growth Factors | 7 | 1995 | 98 | 0.580 |
Why?
|
| Clinical Trials, Phase II as Topic | 10 | 2021 | 639 | 0.580 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 14 | 2014 | 631 | 0.580 |
Why?
|
| Aged, 80 and over | 58 | 2021 | 59598 | 0.570 |
Why?
|
| Benzothiazoles | 1 | 2018 | 248 | 0.570 |
Why?
|
| Female | 187 | 2024 | 397113 | 0.560 |
Why?
|
| Chromans | 6 | 2004 | 116 | 0.540 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 16 | 2015 | 892 | 0.540 |
Why?
|
| Immunoconjugates | 2 | 2021 | 975 | 0.530 |
Why?
|
| Colony-Stimulating Factors | 13 | 2007 | 218 | 0.530 |
Why?
|
| Male | 160 | 2024 | 364641 | 0.520 |
Why?
|
| Stromal Cells | 12 | 2004 | 1336 | 0.510 |
Why?
|
| Treatment Failure | 10 | 2017 | 2660 | 0.500 |
Why?
|
| Survival Analysis | 27 | 2024 | 10098 | 0.500 |
Why?
|
| Thiazoles | 6 | 2009 | 1542 | 0.480 |
Why?
|
| Survival Rate | 26 | 2021 | 12828 | 0.480 |
Why?
|
| Molecular Targeted Therapy | 8 | 2021 | 2824 | 0.470 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2018 | 494 | 0.470 |
Why?
|
| Enzyme Inhibitors | 5 | 2002 | 3726 | 0.460 |
Why?
|
| Receptor, trkA | 5 | 2023 | 159 | 0.460 |
Why?
|
| Benzofurans | 1 | 2014 | 138 | 0.460 |
Why?
|
| Oncogene Proteins, Fusion | 10 | 2023 | 1608 | 0.440 |
Why?
|
| Clinical Trials as Topic | 16 | 2024 | 8052 | 0.440 |
Why?
|
| Benzoquinones | 2 | 2013 | 198 | 0.430 |
Why?
|
| Young Adult | 44 | 2022 | 60048 | 0.420 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2022 | 5394 | 0.420 |
Why?
|
| Compassionate Use Trials | 1 | 2013 | 50 | 0.420 |
Why?
|
| Mutation | 41 | 2020 | 30211 | 0.420 |
Why?
|
| Quinolines | 3 | 2013 | 770 | 0.410 |
Why?
|
| Decision Making | 4 | 2021 | 3952 | 0.410 |
Why?
|
| Lung Neoplasms | 14 | 2022 | 13499 | 0.410 |
Why?
|
| Salvage Therapy | 6 | 2019 | 1273 | 0.400 |
Why?
|
| Lactams, Macrocyclic | 2 | 2013 | 319 | 0.400 |
Why?
|
| Biological Products | 1 | 2021 | 948 | 0.390 |
Why?
|
| Retroperitoneal Neoplasms | 5 | 2004 | 335 | 0.390 |
Why?
|
| Phthalazines | 1 | 2014 | 397 | 0.390 |
Why?
|
| Hydroxamic Acids | 1 | 2014 | 483 | 0.390 |
Why?
|
| Pyrrolidinones | 1 | 2012 | 116 | 0.390 |
Why?
|
| Liposarcoma, Myxoid | 3 | 2024 | 60 | 0.380 |
Why?
|
| Outpatients | 1 | 2019 | 1600 | 0.370 |
Why?
|
| Sulfonamides | 5 | 2021 | 1982 | 0.370 |
Why?
|
| Serine | 1 | 2015 | 831 | 0.370 |
Why?
|
| Gene Fusion | 4 | 2023 | 356 | 0.370 |
Why?
|
| Translocation, Genetic | 5 | 2012 | 1390 | 0.360 |
Why?
|
| Deoxycytidine | 4 | 2020 | 887 | 0.360 |
Why?
|
| Disease Progression | 22 | 2018 | 13665 | 0.350 |
Why?
|
| Carbolines | 2 | 2024 | 295 | 0.340 |
Why?
|
| Microphthalmia-Associated Transcription Factor | 1 | 2012 | 257 | 0.340 |
Why?
|
| Infusions, Intravenous | 12 | 2011 | 2227 | 0.340 |
Why?
|
| Neoplasm Metastasis | 12 | 2024 | 4904 | 0.340 |
Why?
|
| HSP90 Heat-Shock Proteins | 4 | 2016 | 422 | 0.340 |
Why?
|
| PPAR gamma | 2 | 2012 | 485 | 0.340 |
Why?
|
| Hematinics | 3 | 2005 | 282 | 0.330 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2014 | 777 | 0.330 |
Why?
|
| Administration, Oral | 10 | 2021 | 4030 | 0.330 |
Why?
|
| Adolescent | 40 | 2023 | 89155 | 0.330 |
Why?
|
| Evidence-Based Medicine | 2 | 2021 | 3701 | 0.320 |
Why?
|
| Cisplatin | 2 | 2015 | 1658 | 0.320 |
Why?
|
| Retreatment | 3 | 2017 | 598 | 0.320 |
Why?
|
| Proto-Oncogene Proteins c-met | 2 | 2012 | 563 | 0.320 |
Why?
|
| Succinate Dehydrogenase | 4 | 2019 | 148 | 0.310 |
Why?
|
| Carcinoma, Small Cell | 3 | 1996 | 419 | 0.310 |
Why?
|
| Oncogene Proteins | 5 | 2004 | 717 | 0.310 |
Why?
|
| Oncogenes | 6 | 2020 | 1232 | 0.310 |
Why?
|
| Recombinant Proteins | 26 | 2009 | 6515 | 0.310 |
Why?
|
| Clinical Trials, Phase III as Topic | 6 | 2021 | 878 | 0.310 |
Why?
|
| Dose-Response Relationship, Drug | 19 | 2016 | 10757 | 0.300 |
Why?
|
| Chemotherapy, Adjuvant | 16 | 2017 | 3553 | 0.300 |
Why?
|
| Heart | 1 | 2021 | 4444 | 0.290 |
Why?
|
| Inpatients | 1 | 2019 | 2570 | 0.290 |
Why?
|
| Combined Modality Therapy | 16 | 2017 | 8535 | 0.290 |
Why?
|
| Mesoderm | 3 | 2002 | 679 | 0.290 |
Why?
|
| MAP Kinase Kinase 4 | 1 | 2007 | 147 | 0.290 |
Why?
|
| Growth Substances | 7 | 2002 | 759 | 0.280 |
Why?
|
| Thrombospondin 1 | 1 | 2008 | 257 | 0.280 |
Why?
|
| Research Subjects | 2 | 2007 | 249 | 0.280 |
Why?
|
| Hemangiosarcoma | 2 | 2020 | 215 | 0.260 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 5 | 2020 | 547 | 0.250 |
Why?
|
| Benzenesulfonates | 3 | 2012 | 170 | 0.250 |
Why?
|
| Vascular Endothelial Growth Factor A | 6 | 2011 | 3514 | 0.250 |
Why?
|
| Neovascularization, Pathologic | 4 | 2012 | 2630 | 0.250 |
Why?
|
| Immunohistochemistry | 17 | 2019 | 11068 | 0.250 |
Why?
|
| DNA Mutational Analysis | 12 | 2020 | 4114 | 0.250 |
Why?
|
| Gene Expression Regulation, Neoplastic | 12 | 2021 | 8637 | 0.250 |
Why?
|
| Drug Monitoring | 2 | 2009 | 964 | 0.240 |
Why?
|
| Antigens, Neoplasm | 4 | 2022 | 1997 | 0.240 |
Why?
|
| Rare Diseases | 2 | 2021 | 631 | 0.240 |
Why?
|
| Molecular Biology | 2 | 2011 | 573 | 0.240 |
Why?
|
| Double-Blind Method | 11 | 2015 | 12464 | 0.240 |
Why?
|
| Proportional Hazards Models | 11 | 2017 | 12536 | 0.240 |
Why?
|
| Receptor, IGF Type 1 | 3 | 2012 | 384 | 0.230 |
Why?
|
| Ovarian Neoplasms | 3 | 2021 | 4915 | 0.230 |
Why?
|
| Proto-Oncogene Proteins | 6 | 2022 | 4525 | 0.230 |
Why?
|
| Biopsy, Needle | 3 | 2012 | 1622 | 0.220 |
Why?
|
| Safety | 5 | 2016 | 1159 | 0.220 |
Why?
|
| Sarcoma, Alveolar Soft Part | 2 | 2015 | 44 | 0.220 |
Why?
|
| Fusion Proteins, bcr-abl | 2 | 2007 | 430 | 0.220 |
Why?
|
| Neoplasm Staging | 15 | 2019 | 11221 | 0.220 |
Why?
|
| Cell Proliferation | 13 | 2021 | 10470 | 0.220 |
Why?
|
| Receptor, trkC | 2 | 2020 | 63 | 0.210 |
Why?
|
| Sarcoma, Clear Cell | 2 | 2015 | 72 | 0.210 |
Why?
|
| Fatigue | 5 | 2017 | 1557 | 0.210 |
Why?
|
| Oligopeptides | 1 | 2008 | 1194 | 0.210 |
Why?
|
| Bone Marrow Diseases | 3 | 1994 | 234 | 0.210 |
Why?
|
| Tetrahydronaphthalenes | 1 | 2003 | 85 | 0.210 |
Why?
|
| United States Food and Drug Administration | 2 | 2021 | 1671 | 0.200 |
Why?
|
| Neoplasms, Connective Tissue | 1 | 2002 | 36 | 0.200 |
Why?
|
| Prognosis | 24 | 2022 | 29979 | 0.200 |
Why?
|
| Breast Neoplasms | 15 | 2020 | 21206 | 0.200 |
Why?
|
| Gene Expression Profiling | 7 | 2020 | 9536 | 0.200 |
Why?
|
| Informed Consent | 2 | 2007 | 1010 | 0.200 |
Why?
|
| Receptor, trkB | 2 | 2020 | 123 | 0.200 |
Why?
|
| Alanine Transaminase | 3 | 2017 | 606 | 0.200 |
Why?
|
| Retrospective Studies | 29 | 2022 | 81746 | 0.200 |
Why?
|
| Child | 17 | 2023 | 80906 | 0.200 |
Why?
|
| Quality of Life | 11 | 2021 | 13489 | 0.200 |
Why?
|
| Phosphorylation | 15 | 2014 | 8314 | 0.190 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 4 | 2016 | 861 | 0.190 |
Why?
|
| Membrane Proteins | 6 | 2022 | 7876 | 0.190 |
Why?
|
| Triazoles | 3 | 2019 | 904 | 0.190 |
Why?
|
| Placebos | 3 | 2012 | 1667 | 0.190 |
Why?
|
| Clinical Trials, Phase I as Topic | 4 | 2019 | 329 | 0.190 |
Why?
|
| Receptors, CCR | 1 | 2021 | 37 | 0.180 |
Why?
|
| International Cooperation | 3 | 2018 | 1434 | 0.180 |
Why?
|
| Xenograft Model Antitumor Assays | 6 | 2021 | 3609 | 0.180 |
Why?
|
| Carcinoma, Renal Cell | 3 | 2012 | 3187 | 0.180 |
Why?
|
| Drug Resistance, Multiple | 1 | 2002 | 255 | 0.180 |
Why?
|
| Transcription Factors | 8 | 2021 | 12165 | 0.180 |
Why?
|
| Positron-Emission Tomography | 8 | 2013 | 6668 | 0.180 |
Why?
|
| SKP Cullin F-Box Protein Ligases | 1 | 2021 | 174 | 0.180 |
Why?
|
| Sulfides | 1 | 2021 | 171 | 0.180 |
Why?
|
| Leukopenia | 2 | 2019 | 212 | 0.180 |
Why?
|
| Antibodies, Monoclonal | 4 | 2012 | 9252 | 0.180 |
Why?
|
| Platinum | 1 | 2002 | 222 | 0.170 |
Why?
|
| Fibromatosis, Aggressive | 3 | 2008 | 125 | 0.170 |
Why?
|
| Disease Management | 4 | 2019 | 2533 | 0.170 |
Why?
|
| Neoplasms, Muscle Tissue | 2 | 2010 | 68 | 0.170 |
Why?
|
| Time Factors | 19 | 2019 | 40214 | 0.170 |
Why?
|
| Growth Differentiation Factor 15 | 1 | 2021 | 199 | 0.170 |
Why?
|
| Thigh | 2 | 1999 | 238 | 0.170 |
Why?
|
| Health Records, Personal | 1 | 2020 | 127 | 0.160 |
Why?
|
| Neoplasm Proteins | 4 | 2002 | 3601 | 0.160 |
Why?
|
| Patient Participation | 3 | 2020 | 1446 | 0.160 |
Why?
|
| Practice Guidelines as Topic | 3 | 2007 | 7445 | 0.160 |
Why?
|
| Receptors, Nerve Growth Factor | 1 | 2019 | 199 | 0.160 |
Why?
|
| Drug Dosage Calculations | 2 | 2021 | 117 | 0.160 |
Why?
|
| Hemoglobin A | 1 | 1998 | 84 | 0.160 |
Why?
|
| Polyethylene Glycols | 4 | 2021 | 1196 | 0.150 |
Why?
|
| Sarcoma, Small Cell | 1 | 1998 | 17 | 0.150 |
Why?
|
| Signal Transduction | 16 | 2018 | 23642 | 0.150 |
Why?
|
| Drug Labeling | 1 | 2020 | 250 | 0.150 |
Why?
|
| Epoetin Alfa | 4 | 2002 | 78 | 0.150 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2019 | 127 | 0.150 |
Why?
|
| Hypertension | 4 | 2014 | 8616 | 0.150 |
Why?
|
| United States | 17 | 2021 | 73027 | 0.150 |
Why?
|
| Vascular Neoplasms | 2 | 2011 | 167 | 0.150 |
Why?
|
| Stomach Neoplasms | 2 | 2014 | 1481 | 0.140 |
Why?
|
| Somatostatin | 1 | 1999 | 458 | 0.140 |
Why?
|
| Drug Approval | 2 | 2021 | 820 | 0.140 |
Why?
|
| Cyclin D1 | 1 | 2019 | 453 | 0.140 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 2 | 2021 | 1144 | 0.140 |
Why?
|
| Tomography, X-Ray Computed | 16 | 2018 | 20757 | 0.140 |
Why?
|
| Adoptive Transfer | 1 | 2019 | 825 | 0.140 |
Why?
|
| Chromosome Aberrations | 5 | 2019 | 1777 | 0.140 |
Why?
|
| Receptors, Antigen, T-Cell | 3 | 2022 | 2568 | 0.140 |
Why?
|
| Aspartate Aminotransferases | 2 | 2017 | 414 | 0.140 |
Why?
|
| Gastrectomy | 2 | 2019 | 693 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-akt | 4 | 2014 | 2456 | 0.130 |
Why?
|
| Cyclin-Dependent Kinase 6 | 2 | 2022 | 353 | 0.130 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2021 | 463 | 0.130 |
Why?
|
| Leukemia, Myeloid | 2 | 2009 | 693 | 0.130 |
Why?
|
| Piperidines | 2 | 2002 | 1667 | 0.130 |
Why?
|
| Isoindoles | 1 | 2016 | 36 | 0.130 |
Why?
|
| Hematopoietic Stem Cells | 8 | 1996 | 3409 | 0.130 |
Why?
|
| Uterus | 1 | 2020 | 663 | 0.130 |
Why?
|
| Cytokines | 5 | 2019 | 7450 | 0.130 |
Why?
|
| Muscle Proteins | 1 | 2021 | 1165 | 0.130 |
Why?
|
| Hemoglobins | 6 | 2005 | 1531 | 0.130 |
Why?
|
| Fluorodeoxyglucose F18 | 5 | 2012 | 2054 | 0.130 |
Why?
|
| Tumor Microenvironment | 4 | 2022 | 3948 | 0.130 |
Why?
|
| Congresses as Topic | 1 | 2021 | 812 | 0.130 |
Why?
|
| Randomized Controlled Trials as Topic | 10 | 2019 | 10396 | 0.130 |
Why?
|
| Drug Design | 3 | 2007 | 1045 | 0.130 |
Why?
|
| Cyclin-Dependent Kinase 4 | 2 | 2022 | 564 | 0.130 |
Why?
|
| Data Collection | 2 | 2024 | 3326 | 0.130 |
Why?
|
| Tumor Cells, Cultured | 8 | 2021 | 6119 | 0.130 |
Why?
|
| Cell Line, Tumor | 13 | 2021 | 17128 | 0.120 |
Why?
|
| Prospective Studies | 15 | 2022 | 54924 | 0.120 |
Why?
|
| Mesothelioma | 2 | 1993 | 774 | 0.120 |
Why?
|
| Hematologic Neoplasms | 3 | 2008 | 1907 | 0.120 |
Why?
|
| Karyopherins | 1 | 2016 | 134 | 0.120 |
Why?
|
| Rhabdoid Tumor | 1 | 2017 | 211 | 0.120 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2017 | 706 | 0.120 |
Why?
|
| Chondrosarcoma | 2 | 2013 | 305 | 0.120 |
Why?
|
| Republic of Korea | 2 | 2015 | 591 | 0.120 |
Why?
|
| Pyridones | 1 | 2020 | 819 | 0.120 |
Why?
|
| T-Lymphocytes | 3 | 2019 | 10264 | 0.120 |
Why?
|
| Area Under Curve | 4 | 2009 | 1642 | 0.120 |
Why?
|
| Animals | 34 | 2022 | 169222 | 0.120 |
Why?
|
| Health Care Sector | 1 | 2016 | 196 | 0.120 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 3 | 2008 | 662 | 0.120 |
Why?
|
| Abdominal Neoplasms | 2 | 2010 | 287 | 0.120 |
Why?
|
| Mice, Nude | 6 | 2019 | 3620 | 0.120 |
Why?
|
| Interleukin-3 | 3 | 1994 | 425 | 0.120 |
Why?
|
| Hydrazines | 1 | 2016 | 223 | 0.120 |
Why?
|
| Neoplasms, Second Primary | 1 | 2022 | 1061 | 0.120 |
Why?
|
| Cancer Vaccines | 2 | 2015 | 1041 | 0.120 |
Why?
|
| Nausea | 1 | 2017 | 682 | 0.120 |
Why?
|
| Receptors, Progesterone | 2 | 2013 | 1160 | 0.120 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2017 | 325 | 0.110 |
Why?
|
| Thrombopoietin | 3 | 2001 | 225 | 0.110 |
Why?
|
| Multicenter Studies as Topic | 4 | 2007 | 1736 | 0.110 |
Why?
|
| Exons | 6 | 2014 | 2393 | 0.110 |
Why?
|
| Vascular Endothelial Growth Factors | 2 | 2012 | 748 | 0.110 |
Why?
|
| Paclitaxel | 4 | 2008 | 1728 | 0.110 |
Why?
|
| Neoadjuvant Therapy | 3 | 2012 | 2902 | 0.110 |
Why?
|
| Membrane Glycoproteins | 3 | 2020 | 3710 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 2014 | 287 | 0.110 |
Why?
|
| Genes, Wilms Tumor | 1 | 1993 | 92 | 0.110 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2014 | 205 | 0.110 |
Why?
|
| Phosphatidylinositol 3-Kinase | 1 | 2014 | 125 | 0.110 |
Why?
|
| Chaperonins | 1 | 2013 | 58 | 0.110 |
Why?
|
| Alopecia | 1 | 2017 | 416 | 0.100 |
Why?
|
| Drug Substitution | 1 | 2015 | 291 | 0.100 |
Why?
|
| Patient Satisfaction | 1 | 2005 | 3488 | 0.100 |
Why?
|
| Dystrophin | 1 | 2014 | 284 | 0.100 |
Why?
|
| Point Mutation | 2 | 2000 | 1594 | 0.100 |
Why?
|
| Mesna | 3 | 2004 | 62 | 0.100 |
Why?
|
| Research Support as Topic | 1 | 2016 | 696 | 0.100 |
Why?
|
| Sequence Deletion | 3 | 2007 | 1494 | 0.100 |
Why?
|
| Mucous Membrane | 2 | 2013 | 659 | 0.100 |
Why?
|
| Receptors, Granulocyte Colony-Stimulating Factor | 1 | 1991 | 21 | 0.100 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2017 | 724 | 0.100 |
Why?
|
| Patient Selection | 5 | 2014 | 4258 | 0.100 |
Why?
|
| Desmoplastic Small Round Cell Tumor | 1 | 2012 | 33 | 0.100 |
Why?
|
| Apoptosis | 9 | 2021 | 9521 | 0.100 |
Why?
|
| Cell Survival | 5 | 2021 | 5772 | 0.100 |
Why?
|
| Follow-Up Studies | 14 | 2021 | 39345 | 0.100 |
Why?
|
| Stomatitis | 2 | 2011 | 271 | 0.100 |
Why?
|
| Protein Kinase C | 2 | 2008 | 1207 | 0.100 |
Why?
|
| Isoenzymes | 2 | 2008 | 1688 | 0.100 |
Why?
|
| Muscular Dystrophies | 1 | 2014 | 393 | 0.100 |
Why?
|
| Genes | 3 | 1991 | 1824 | 0.100 |
Why?
|
| HLA-A Antigens | 2 | 2024 | 223 | 0.090 |
Why?
|
| ras Proteins | 2 | 2014 | 1054 | 0.090 |
Why?
|
| Sunlight | 1 | 2013 | 337 | 0.090 |
Why?
|
| Homeodomain Proteins | 1 | 2021 | 2429 | 0.090 |
Why?
|
| Fever | 3 | 2009 | 1613 | 0.090 |
Why?
|
| Gene Amplification | 2 | 2013 | 1088 | 0.090 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2014 | 287 | 0.090 |
Why?
|
| Stem Cell Factor | 3 | 2004 | 194 | 0.090 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2017 | 1120 | 0.090 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 7 | 2001 | 5717 | 0.090 |
Why?
|
| Receptors, Estrogen | 2 | 2013 | 2253 | 0.090 |
Why?
|
| Multivariate Analysis | 3 | 2021 | 12075 | 0.090 |
Why?
|
| Endothelin-1 | 1 | 2012 | 296 | 0.090 |
Why?
|
| Genes, ras | 2 | 2008 | 657 | 0.090 |
Why?
|
| Tomography, Emission-Computed | 3 | 2003 | 1126 | 0.090 |
Why?
|
| Diagnostic Imaging | 3 | 2012 | 3532 | 0.090 |
Why?
|
| Extracellular Fluid | 1 | 2012 | 165 | 0.090 |
Why?
|
| Comprehension | 2 | 2007 | 639 | 0.090 |
Why?
|
| Radiotherapy, Adjuvant | 5 | 2002 | 1788 | 0.090 |
Why?
|
| Cross-Over Studies | 3 | 2012 | 2107 | 0.090 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2016 | 719 | 0.090 |
Why?
|
| Cell Respiration | 1 | 2010 | 201 | 0.090 |
Why?
|
| Age Factors | 5 | 2021 | 18407 | 0.090 |
Why?
|
| Drug Industry | 1 | 2016 | 791 | 0.090 |
Why?
|
| Half-Life | 2 | 2009 | 651 | 0.090 |
Why?
|
| Leukemia, Myelomonocytic, Acute | 1 | 1989 | 38 | 0.080 |
Why?
|
| Extremities | 4 | 2004 | 870 | 0.080 |
Why?
|
| Drug Delivery Systems | 2 | 2015 | 2230 | 0.080 |
Why?
|
| Interferon-alpha | 1 | 2014 | 910 | 0.080 |
Why?
|
| Serous Membrane | 1 | 1989 | 22 | 0.080 |
Why?
|
| Cell Division | 8 | 2004 | 4473 | 0.080 |
Why?
|
| Cyclophosphamide | 5 | 2008 | 2227 | 0.080 |
Why?
|
| Granuloma, Plasma Cell | 1 | 2010 | 80 | 0.080 |
Why?
|
| Rhabdomyolysis | 1 | 2011 | 150 | 0.080 |
Why?
|
| Irritants | 1 | 2009 | 43 | 0.080 |
Why?
|
| Aromatase Inhibitors | 1 | 2013 | 519 | 0.080 |
Why?
|
| Kidney Neoplasms | 4 | 2012 | 4282 | 0.080 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2010 | 2889 | 0.080 |
Why?
|
| Connective Tissue | 2 | 2022 | 425 | 0.080 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2019 | 1512 | 0.080 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2019 | 2846 | 0.080 |
Why?
|
| Phosphatidylinositol 3-Kinases | 5 | 2013 | 2884 | 0.080 |
Why?
|
| Cell Cycle | 6 | 2017 | 2932 | 0.080 |
Why?
|
| Perivascular Epithelioid Cell Neoplasms | 1 | 2010 | 78 | 0.080 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 5 | 2008 | 183 | 0.080 |
Why?
|
| Mucositis | 1 | 2010 | 108 | 0.080 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-3 | 1 | 2009 | 118 | 0.080 |
Why?
|
| Taxoids | 1 | 2012 | 665 | 0.080 |
Why?
|
| Mice | 18 | 2022 | 82024 | 0.080 |
Why?
|
| Thiophenes | 1 | 2013 | 570 | 0.080 |
Why?
|
| Biological Factors | 1 | 1989 | 155 | 0.080 |
Why?
|
| Liver | 4 | 2017 | 7574 | 0.080 |
Why?
|
| Nitriles | 1 | 2013 | 980 | 0.080 |
Why?
|
| Stroke Volume | 2 | 2021 | 5624 | 0.080 |
Why?
|
| Karyotyping | 3 | 2005 | 1176 | 0.080 |
Why?
|
| Skin Ulcer | 1 | 2009 | 130 | 0.080 |
Why?
|
| Ventricular Function, Left | 1 | 2021 | 3941 | 0.070 |
Why?
|
| Carboplatin | 3 | 2008 | 791 | 0.070 |
Why?
|
| Vaccines, Subunit | 1 | 2008 | 159 | 0.070 |
Why?
|
| Cardiotoxins | 1 | 2007 | 36 | 0.070 |
Why?
|
| Diarrhea | 1 | 2015 | 1320 | 0.070 |
Why?
|
| Thromboplastin | 1 | 1989 | 289 | 0.070 |
Why?
|
| Soft Tissue Injuries | 1 | 2009 | 173 | 0.070 |
Why?
|
| Drug Tolerance | 1 | 2009 | 365 | 0.070 |
Why?
|
| Pharmacogenetics | 1 | 2012 | 682 | 0.070 |
Why?
|
| Drug Discovery | 1 | 2015 | 1068 | 0.070 |
Why?
|
| Mesentery | 1 | 2008 | 202 | 0.070 |
Why?
|
| Hematopoiesis | 6 | 1994 | 2059 | 0.070 |
Why?
|
| Solubility | 1 | 2009 | 1083 | 0.070 |
Why?
|
| Transcription, Genetic | 6 | 2005 | 7612 | 0.070 |
Why?
|
| Patients | 1 | 2014 | 908 | 0.070 |
Why?
|
| Enzyme Activation | 6 | 2013 | 3587 | 0.070 |
Why?
|
| Blood Transfusion | 4 | 2005 | 1308 | 0.070 |
Why?
|
| Melanoma | 3 | 2013 | 5706 | 0.070 |
Why?
|
| Cardiovascular Diseases | 3 | 2021 | 15660 | 0.070 |
Why?
|
| Cell Movement | 3 | 2014 | 5209 | 0.070 |
Why?
|
| Blood Coagulation Factors | 1 | 1989 | 371 | 0.070 |
Why?
|
| Imidazoles | 1 | 2013 | 1168 | 0.070 |
Why?
|
| In Situ Hybridization, Fluorescence | 5 | 2014 | 2510 | 0.070 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2008 | 705 | 0.070 |
Why?
|
| Patient Education as Topic | 3 | 2007 | 2336 | 0.070 |
Why?
|
| Protein Kinase C-delta | 1 | 2007 | 115 | 0.070 |
Why?
|
| Blotting, Western | 5 | 2016 | 5024 | 0.070 |
Why?
|
| Fatal Outcome | 3 | 2000 | 1836 | 0.070 |
Why?
|
| Benzimidazoles | 1 | 2012 | 863 | 0.070 |
Why?
|
| Research Design | 3 | 2024 | 6211 | 0.070 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2009 | 695 | 0.070 |
Why?
|
| Genomics | 2 | 2020 | 5925 | 0.070 |
Why?
|
| Cell Differentiation | 6 | 2014 | 11665 | 0.070 |
Why?
|
| Diagnosis, Differential | 4 | 2004 | 13000 | 0.060 |
Why?
|
| Academic Medical Centers | 1 | 2016 | 2783 | 0.060 |
Why?
|
| Genotype | 5 | 2016 | 13042 | 0.060 |
Why?
|
| K562 Cells | 1 | 2007 | 644 | 0.060 |
Why?
|
| Platelet-Derived Growth Factor | 3 | 2006 | 617 | 0.060 |
Why?
|
| Proteins | 2 | 2019 | 6009 | 0.060 |
Why?
|
| North America | 1 | 2009 | 1289 | 0.060 |
Why?
|
| Kidney Diseases | 1 | 2016 | 2100 | 0.060 |
Why?
|
| Australia | 1 | 2009 | 1265 | 0.060 |
Why?
|
| Remission Induction | 3 | 2002 | 2409 | 0.060 |
Why?
|
| Filgrastim | 4 | 2009 | 131 | 0.060 |
Why?
|
| Consensus | 3 | 2022 | 3210 | 0.060 |
Why?
|
| Teaching Materials | 1 | 2005 | 85 | 0.060 |
Why?
|
| Rhabdomyosarcoma | 2 | 2014 | 358 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2019 | 18062 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 3 | 2009 | 6071 | 0.060 |
Why?
|
| Europe | 2 | 2009 | 3437 | 0.060 |
Why?
|
| Proteinuria | 1 | 2008 | 612 | 0.060 |
Why?
|
| Forecasting | 3 | 2005 | 2945 | 0.060 |
Why?
|
| Bone Cysts, Aneurysmal | 1 | 2005 | 70 | 0.060 |
Why?
|
| Platelet Count | 2 | 2002 | 787 | 0.060 |
Why?
|
| Dermatofibrosarcoma | 1 | 2005 | 49 | 0.060 |
Why?
|
| Colorectal Neoplasms | 2 | 2021 | 6973 | 0.060 |
Why?
|
| Gene Expression | 4 | 2022 | 7597 | 0.060 |
Why?
|
| Vena Cava, Inferior | 1 | 2007 | 463 | 0.060 |
Why?
|
| Interferon-gamma | 2 | 1989 | 3159 | 0.060 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2014 | 3798 | 0.060 |
Why?
|
| History, 18th Century | 1 | 2004 | 206 | 0.060 |
Why?
|
| Niacinamide | 3 | 2012 | 418 | 0.060 |
Why?
|
| Clone Cells | 1 | 2007 | 1669 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2005 | 418 | 0.050 |
Why?
|
| Biopsy | 4 | 2019 | 6786 | 0.050 |
Why?
|
| CHO Cells | 3 | 2019 | 1379 | 0.050 |
Why?
|
| Nurse's Role | 1 | 2005 | 188 | 0.050 |
Why?
|
| Injections, Subcutaneous | 2 | 2002 | 686 | 0.050 |
Why?
|
| Patient-Centered Care | 1 | 2013 | 1444 | 0.050 |
Why?
|
| Nitric Oxide | 1 | 2012 | 2146 | 0.050 |
Why?
|
| Toremifene | 1 | 2003 | 24 | 0.050 |
Why?
|
| Telomerase | 1 | 2008 | 751 | 0.050 |
Why?
|
| Syndrome | 2 | 2010 | 3271 | 0.050 |
Why?
|
| Estrogen Receptor Modulators | 1 | 2003 | 58 | 0.050 |
Why?
|
| DNA-Binding Proteins | 4 | 2005 | 9614 | 0.050 |
Why?
|
| Gene Rearrangement | 2 | 2005 | 1141 | 0.050 |
Why?
|
| Advisory Committees | 1 | 2007 | 797 | 0.050 |
Why?
|
| Analysis of Variance | 2 | 2015 | 6228 | 0.050 |
Why?
|
| Tumor Burden | 3 | 2014 | 1904 | 0.050 |
Why?
|
| Leukocyte Count | 4 | 2009 | 1609 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2016 | 4576 | 0.050 |
Why?
|
| Protective Agents | 1 | 2003 | 150 | 0.050 |
Why?
|
| Models, Economic | 1 | 2007 | 719 | 0.050 |
Why?
|
| Sex Factors | 2 | 2011 | 10627 | 0.050 |
Why?
|
| Neoplasms, Experimental | 1 | 2007 | 1230 | 0.050 |
Why?
|
| Infrared Rays | 1 | 2003 | 249 | 0.050 |
Why?
|
| Antigens, CD34 | 1 | 2004 | 657 | 0.050 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2012 | 1335 | 0.050 |
Why?
|
| Bone Marrow Transplantation | 3 | 1996 | 2710 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2022 | 185 | 0.050 |
Why?
|
| Peritoneal Neoplasms | 1 | 2008 | 707 | 0.050 |
Why?
|
| Enhancer Elements, Genetic | 2 | 2019 | 1367 | 0.050 |
Why?
|
| RNA, Small Interfering | 4 | 2014 | 3428 | 0.050 |
Why?
|
| Antigens, Surface | 2 | 2001 | 1617 | 0.050 |
Why?
|
| Multidrug Resistance-Associated Proteins | 1 | 2002 | 105 | 0.050 |
Why?
|
| Hypothyroidism | 1 | 2006 | 667 | 0.050 |
Why?
|
| Cell Cycle Proteins | 1 | 2013 | 3443 | 0.050 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2024 | 296 | 0.050 |
Why?
|
| Skin Neoplasms | 3 | 2013 | 5861 | 0.050 |
Why?
|
| Blood Pressure | 3 | 2012 | 8540 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 1989 | 4351 | 0.050 |
Why?
|
| Germ-Line Mutation | 2 | 2010 | 1883 | 0.050 |
Why?
|
| Interleukin-11 | 1 | 2001 | 59 | 0.050 |
Why?
|
| Cohort Studies | 9 | 2014 | 41749 | 0.040 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2013 | 1966 | 0.040 |
Why?
|
| Feasibility Studies | 4 | 2009 | 5314 | 0.040 |
Why?
|
| Rats | 3 | 2021 | 23751 | 0.040 |
Why?
|
| Drug Interactions | 1 | 2005 | 1419 | 0.040 |
Why?
|
| Inflammation | 1 | 2020 | 10871 | 0.040 |
Why?
|
| Haplorhini | 1 | 2021 | 523 | 0.040 |
Why?
|
| Thyroid Hormones | 1 | 2003 | 408 | 0.040 |
Why?
|
| Fibroblast Growth Factor 4 | 1 | 2019 | 28 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 2 | 2022 | 2040 | 0.040 |
Why?
|
| Indium Radioisotopes | 1 | 1999 | 116 | 0.040 |
Why?
|
| GTP Phosphohydrolases | 2 | 2013 | 525 | 0.040 |
Why?
|
| Neuroectodermal Tumors | 1 | 1999 | 23 | 0.040 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2019 | 89 | 0.040 |
Why?
|
| Leukemia, Myeloid, Acute | 4 | 2006 | 3626 | 0.040 |
Why?
|
| Genes, p53 | 2 | 2012 | 711 | 0.040 |
Why?
|
| Mitotic Index | 2 | 2014 | 160 | 0.040 |
Why?
|
| Angiomyolipoma | 1 | 2001 | 189 | 0.040 |
Why?
|
| Case Management | 1 | 2001 | 277 | 0.040 |
Why?
|
| Erythrocyte Transfusion | 2 | 2001 | 575 | 0.040 |
Why?
|
| HEK293 Cells | 2 | 2019 | 4289 | 0.040 |
Why?
|
| Gene Expression Regulation | 4 | 1990 | 11930 | 0.040 |
Why?
|
| Rectal Neoplasms | 1 | 2008 | 1183 | 0.040 |
Why?
|
| Base Sequence | 6 | 2008 | 12418 | 0.040 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2003 | 617 | 0.040 |
Why?
|
| Guidelines as Topic | 1 | 2005 | 1395 | 0.040 |
Why?
|
| Vinblastine | 3 | 2008 | 487 | 0.040 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 2019 | 194 | 0.040 |
Why?
|
| Evolution, Molecular | 1 | 2007 | 1896 | 0.040 |
Why?
|
| Physical Examination | 1 | 2005 | 1263 | 0.040 |
Why?
|
| Risk Factors | 11 | 2022 | 74936 | 0.040 |
Why?
|
| Octreotide | 1 | 1999 | 156 | 0.040 |
Why?
|
| Radiation Tolerance | 1 | 2001 | 476 | 0.040 |
Why?
|
| Odds Ratio | 2 | 2008 | 9666 | 0.040 |
Why?
|
| Disease Models, Animal | 2 | 2022 | 18344 | 0.040 |
Why?
|
| Tamoxifen | 1 | 2003 | 966 | 0.040 |
Why?
|
| Back | 1 | 1998 | 64 | 0.040 |
Why?
|
| Incidence | 4 | 2021 | 21532 | 0.040 |
Why?
|
| Gene Dosage | 2 | 2014 | 1211 | 0.040 |
Why?
|
| DNA, Neoplasm | 5 | 2003 | 1742 | 0.040 |
Why?
|
| Radiotherapy | 1 | 2005 | 1501 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 3 | 2014 | 3618 | 0.040 |
Why?
|
| Liver Neoplasms | 4 | 2002 | 4362 | 0.040 |
Why?
|
| Risk Assessment | 5 | 2012 | 24314 | 0.040 |
Why?
|
| Tissue Distribution | 1 | 2002 | 2299 | 0.040 |
Why?
|
| Health Services Needs and Demand | 1 | 2005 | 1406 | 0.040 |
Why?
|
| Mutation, Missense | 2 | 2013 | 2592 | 0.040 |
Why?
|
| Phosphatidylcholines | 1 | 1999 | 406 | 0.040 |
Why?
|
| Osteosarcoma | 1 | 2003 | 911 | 0.040 |
Why?
|
| Morpholines | 1 | 2020 | 584 | 0.040 |
Why?
|
| Pedigree | 1 | 2005 | 4539 | 0.040 |
Why?
|
| Zinc Fingers | 2 | 2004 | 577 | 0.040 |
Why?
|
| RNA, Messenger | 6 | 1993 | 12797 | 0.040 |
Why?
|
| Dendritic Cells | 1 | 2008 | 2745 | 0.030 |
Why?
|
| Radiography, Interventional | 1 | 2004 | 1130 | 0.030 |
Why?
|
| Cricetulus | 1 | 2019 | 812 | 0.030 |
Why?
|
| SEER Program | 1 | 2022 | 1444 | 0.030 |
Why?
|
| Genetic Complementation Test | 1 | 2017 | 557 | 0.030 |
Why?
|
| Azepines | 1 | 2019 | 329 | 0.030 |
Why?
|
| Macrophage Colony-Stimulating Factor | 3 | 1992 | 186 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2007 | 8120 | 0.030 |
Why?
|
| Protein Kinases | 2 | 2018 | 1610 | 0.030 |
Why?
|
| Japan | 1 | 2021 | 1418 | 0.030 |
Why?
|
| Blotting, Northern | 3 | 1993 | 1550 | 0.030 |
Why?
|
| Radiography | 1 | 2007 | 6983 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2017 | 285 | 0.030 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 1998 | 264 | 0.030 |
Why?
|
| Drug Therapy, Combination | 2 | 2021 | 6314 | 0.030 |
Why?
|
| Interleukin-1 | 2 | 1990 | 1252 | 0.030 |
Why?
|
| Ultrasonography, Interventional | 1 | 2004 | 1523 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 2 | 1996 | 1854 | 0.030 |
Why?
|
| Urogenital Neoplasms | 2 | 2008 | 130 | 0.030 |
Why?
|
| Neuroectodermal Tumors, Primitive | 1 | 1997 | 137 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 1997 | 348 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 7 | 2008 | 36742 | 0.030 |
Why?
|
| Interleukins | 2 | 1992 | 796 | 0.030 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2019 | 1353 | 0.030 |
Why?
|
| Hypoglycemic Agents | 1 | 2008 | 3108 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 1997 | 411 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 3 | 2004 | 1698 | 0.030 |
Why?
|
| Neurofibromin 1 | 1 | 2017 | 190 | 0.030 |
Why?
|
| MAP Kinase Signaling System | 2 | 2013 | 1492 | 0.030 |
Why?
|
| Ligands | 2 | 2000 | 3284 | 0.030 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2020 | 904 | 0.030 |
Why?
|
| Ambulatory Care | 2 | 2005 | 2781 | 0.030 |
Why?
|
| Biphenyl Compounds | 1 | 2020 | 1026 | 0.030 |
Why?
|
| Receptors, Colony-Stimulating Factor | 2 | 1992 | 51 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 5 | 2014 | 16041 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 2013 | 5520 | 0.030 |
Why?
|
| Molecular Sequence Data | 5 | 2008 | 17617 | 0.030 |
Why?
|
| RNA, Neoplasm | 3 | 2000 | 748 | 0.030 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2014 | 1760 | 0.030 |
Why?
|
| Algorithms | 2 | 2013 | 14163 | 0.030 |
Why?
|
| Neutrophils | 3 | 2009 | 3786 | 0.030 |
Why?
|
| Heart Diseases | 1 | 2007 | 2819 | 0.030 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2003 | 1536 | 0.030 |
Why?
|
| Lymphoma | 1 | 2003 | 1897 | 0.030 |
Why?
|
| Interstitial Cells of Cajal | 1 | 2014 | 23 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2022 | 2149 | 0.030 |
Why?
|
| Canada | 1 | 2020 | 2129 | 0.030 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 1999 | 1140 | 0.030 |
Why?
|
| Bone Marrow | 3 | 1996 | 2935 | 0.030 |
Why?
|
| Isoleucine | 1 | 2014 | 111 | 0.030 |
Why?
|
| Germinoma | 1 | 1995 | 132 | 0.030 |
Why?
|
| Pilot Projects | 5 | 2008 | 8740 | 0.030 |
Why?
|
| DNA, Complementary | 3 | 2002 | 1989 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 2016 | 1377 | 0.030 |
Why?
|
| Genetic Engineering | 1 | 2019 | 935 | 0.030 |
Why?
|
| STAT1 Transcription Factor | 2 | 2007 | 343 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2007 | 5536 | 0.030 |
Why?
|
| Cell Dedifferentiation | 1 | 2014 | 125 | 0.030 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 1105 | 0.030 |
Why?
|
| Program Development | 1 | 2020 | 1299 | 0.030 |
Why?
|
| Pentacyclic Triterpenes | 1 | 2013 | 36 | 0.030 |
Why?
|
| Threonine | 1 | 2014 | 273 | 0.030 |
Why?
|
| Oligonucleotide Probes | 1 | 1993 | 416 | 0.030 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2017 | 633 | 0.030 |
Why?
|
| Nephrology | 1 | 2016 | 270 | 0.030 |
Why?
|
| Vincristine | 1 | 1995 | 1040 | 0.030 |
Why?
|
| Triterpenes | 1 | 2013 | 78 | 0.030 |
Why?
|
| Sensitivity and Specificity | 3 | 2007 | 14718 | 0.030 |
Why?
|
| Melanocytes | 1 | 1996 | 509 | 0.030 |
Why?
|
| WT1 Proteins | 1 | 1993 | 183 | 0.030 |
Why?
|
| Endothelium, Vascular | 1 | 2005 | 4427 | 0.030 |
Why?
|
| Leukapheresis | 3 | 2001 | 150 | 0.030 |
Why?
|
| Drug Resistance | 1 | 1998 | 1598 | 0.030 |
Why?
|
| Cells, Cultured | 4 | 2014 | 19017 | 0.030 |
Why?
|
| Kinetics | 3 | 2007 | 6328 | 0.030 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2013 | 464 | 0.030 |
Why?
|
| Muscle Development | 1 | 2014 | 258 | 0.020 |
Why?
|
| Chromosome Deletion | 1 | 2017 | 1384 | 0.020 |
Why?
|
| Genital Neoplasms, Female | 2 | 2008 | 536 | 0.020 |
Why?
|
| Blood Platelets | 1 | 2002 | 2479 | 0.020 |
Why?
|
| Amino Acid Sequence | 4 | 2001 | 13420 | 0.020 |
Why?
|
| Proto-Oncogene Protein c-fli-1 | 1 | 2012 | 104 | 0.020 |
Why?
|
| Genome, Human | 2 | 2020 | 4443 | 0.020 |
Why?
|
| Predictive Value of Tests | 3 | 2009 | 15442 | 0.020 |
Why?
|
| Angiogenic Proteins | 1 | 2012 | 101 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2013 | 547 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 2 | 2017 | 5798 | 0.020 |
Why?
|
| Triglycerides | 1 | 1999 | 2463 | 0.020 |
Why?
|
| Recurrence | 2 | 2001 | 8507 | 0.020 |
Why?
|
| Electron Transport Complex II | 1 | 2010 | 53 | 0.020 |
Why?
|
| Mitosis | 1 | 1996 | 1177 | 0.020 |
Why?
|
| STAT3 Transcription Factor | 2 | 2007 | 874 | 0.020 |
Why?
|
| Reference Values | 2 | 1996 | 4938 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2005 | 4055 | 0.020 |
Why?
|
| Retinoblastoma Protein | 1 | 2014 | 671 | 0.020 |
Why?
|
| Feedback, Physiological | 1 | 2013 | 482 | 0.020 |
Why?
|
| RNA-Binding Protein EWS | 1 | 2012 | 211 | 0.020 |
Why?
|
| Glycine | 1 | 2014 | 672 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2017 | 1505 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2014 | 2014 | 0.020 |
Why?
|
| Gene Library | 1 | 2013 | 1065 | 0.020 |
Why?
|
| Arginine | 1 | 2014 | 932 | 0.020 |
Why?
|
| Receptors, Cell Surface | 2 | 1990 | 2819 | 0.020 |
Why?
|
| Cell Separation | 1 | 1996 | 1729 | 0.020 |
Why?
|
| Lentivirus | 1 | 2013 | 518 | 0.020 |
Why?
|
| Receptors, Growth Factor | 1 | 2010 | 324 | 0.020 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2014 | 1059 | 0.020 |
Why?
|
| Drug Therapy | 1 | 2013 | 504 | 0.020 |
Why?
|
| Cricetinae | 2 | 2003 | 2423 | 0.020 |
Why?
|
| Tyrosine | 2 | 2007 | 1427 | 0.020 |
Why?
|
| Population | 1 | 2009 | 141 | 0.020 |
Why?
|
| Receptor, Macrophage Colony-Stimulating Factor | 1 | 1989 | 94 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 1993 | 1892 | 0.020 |
Why?
|
| Peritoneal Cavity | 1 | 1989 | 135 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2020 | 2953 | 0.020 |
Why?
|
| Body Weight | 2 | 2014 | 4628 | 0.020 |
Why?
|
| Leukemia, Experimental | 1 | 1989 | 225 | 0.020 |
Why?
|
| Paraganglioma | 1 | 2010 | 143 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2012 | 635 | 0.020 |
Why?
|
| Extravasation of Diagnostic and Therapeutic Materials | 1 | 2009 | 101 | 0.020 |
Why?
|
| Cloning, Molecular | 2 | 1991 | 4168 | 0.020 |
Why?
|
| Fibromatosis, Abdominal | 1 | 2008 | 21 | 0.020 |
Why?
|
| Mast Cells | 1 | 1996 | 1405 | 0.020 |
Why?
|
| Depression | 1 | 2008 | 8231 | 0.020 |
Why?
|
| Acute Disease | 2 | 2009 | 7241 | 0.020 |
Why?
|
| Central Nervous System Neoplasms | 2 | 2008 | 928 | 0.020 |
Why?
|
| Research | 2 | 2008 | 1979 | 0.020 |
Why?
|
| Severity of Illness Index | 2 | 2009 | 15944 | 0.020 |
Why?
|
| Proto-Oncogenes | 1 | 1989 | 321 | 0.020 |
Why?
|
| Uteroglobin | 1 | 2008 | 55 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2022 | 4648 | 0.020 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1990 | 781 | 0.020 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2012 | 593 | 0.020 |
Why?
|
| Pressure | 1 | 2012 | 1172 | 0.020 |
Why?
|
| Kidney Failure, Chronic | 1 | 2001 | 2496 | 0.020 |
Why?
|
| Transplantation, Autologous | 3 | 2000 | 2120 | 0.020 |
Why?
|
| Capillary Permeability | 1 | 2012 | 772 | 0.020 |
Why?
|
| Drug Evaluation | 1 | 1989 | 642 | 0.020 |
Why?
|
| Lactones | 1 | 1990 | 316 | 0.020 |
Why?
|
| Neoplasm Seeding | 1 | 2008 | 85 | 0.020 |
Why?
|
| Blood Cells | 1 | 1990 | 309 | 0.020 |
Why?
|
| Health Care Costs | 1 | 2001 | 3239 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 3813 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2014 | 3435 | 0.020 |
Why?
|
| Lymphatic Metastasis | 2 | 2008 | 2908 | 0.020 |
Why?
|
| World Health Organization | 1 | 2014 | 1328 | 0.020 |
Why?
|
| History, 16th Century | 1 | 2007 | 70 | 0.020 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2008 | 197 | 0.020 |
Why?
|
| Protein Subunits | 1 | 2010 | 943 | 0.020 |
Why?
|
| Nonlinear Dynamics | 1 | 2009 | 493 | 0.020 |
Why?
|
| History, 17th Century | 1 | 2007 | 108 | 0.020 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 1994 | 1099 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 1993 | 1666 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 1989 | 640 | 0.020 |
Why?
|
| Pancreatic Neoplasms | 1 | 2005 | 5446 | 0.020 |
Why?
|
| Antigen-Presenting Cells | 1 | 1990 | 960 | 0.020 |
Why?
|
| Endpoint Determination | 1 | 2009 | 592 | 0.020 |
Why?
|
| Consent Forms | 1 | 2007 | 55 | 0.020 |
Why?
|
| Decision Trees | 1 | 2009 | 508 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2014 | 2673 | 0.020 |
Why?
|
| Thyroiditis | 1 | 2006 | 86 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 1991 | 3055 | 0.020 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2010 | 667 | 0.020 |
Why?
|
| Chromosome Mapping | 2 | 1991 | 4618 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2019 | 3834 | 0.020 |
Why?
|
| Chromatin | 1 | 2017 | 2981 | 0.020 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1993 | 1374 | 0.020 |
Why?
|
| Genes, sis | 1 | 2005 | 3 | 0.020 |
Why?
|
| Models, Biological | 2 | 2013 | 9493 | 0.020 |
Why?
|
| Drug Synergism | 1 | 1989 | 1760 | 0.020 |
Why?
|
| DNA Methylation | 1 | 2019 | 4426 | 0.020 |
Why?
|
| Hodgkin Disease | 1 | 1993 | 1383 | 0.020 |
Why?
|
| Necrosis | 1 | 2009 | 1616 | 0.020 |
Why?
|
| Iron | 2 | 1994 | 1813 | 0.020 |
Why?
|
| Financing, Government | 1 | 2008 | 473 | 0.020 |
Why?
|
| Albumins | 1 | 2008 | 577 | 0.020 |
Why?
|
| Mice, Transgenic | 2 | 2008 | 9556 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2014 | 6231 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-sis | 1 | 2006 | 254 | 0.010 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2017 | 3669 | 0.010 |
Why?
|
| Epithelium | 1 | 1989 | 1607 | 0.010 |
Why?
|
| Immunoprecipitation | 1 | 2007 | 874 | 0.010 |
Why?
|
| Anastomosis, Surgical | 1 | 2008 | 992 | 0.010 |
Why?
|
| Catheterization, Central Venous | 1 | 2009 | 537 | 0.010 |
Why?
|
| Device Removal | 1 | 2009 | 643 | 0.010 |
Why?
|
| Myelodysplastic Syndromes | 1 | 1994 | 1399 | 0.010 |
Why?
|
| Hemoglobinometry | 1 | 2004 | 35 | 0.010 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2012 | 1942 | 0.010 |
Why?
|
| Propionates | 1 | 2005 | 180 | 0.010 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2007 | 409 | 0.010 |
Why?
|
| Leukemia | 1 | 1992 | 1519 | 0.010 |
Why?
|
| Bone and Bones | 1 | 1994 | 2589 | 0.010 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 1993 | 1560 | 0.010 |
Why?
|
| Genetic Association Studies | 1 | 2013 | 2744 | 0.010 |
Why?
|
| Drainage | 1 | 2009 | 1183 | 0.010 |
Why?
|
| Mice, Mutant Strains | 1 | 2007 | 1752 | 0.010 |
Why?
|
| Topotecan | 1 | 2004 | 131 | 0.010 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1992 | 2204 | 0.010 |
Why?
|
| Multiprotein Complexes | 1 | 2010 | 1110 | 0.010 |
Why?
|
| Interleukin-6 | 2 | 1990 | 3228 | 0.010 |
Why?
|
| Heart Failure | 1 | 2007 | 11883 | 0.010 |
Why?
|
| Adjuvants, Immunologic | 1 | 2008 | 998 | 0.010 |
Why?
|
| Thyrotropin | 1 | 2006 | 835 | 0.010 |
Why?
|
| Gallium Radioisotopes | 1 | 2003 | 195 | 0.010 |
Why?
|
| Receptors, Immunologic | 1 | 1989 | 1418 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2014 | 4785 | 0.010 |
Why?
|
| Immunoblotting | 1 | 2006 | 1647 | 0.010 |
Why?
|
| Carcinoma | 1 | 2014 | 2330 | 0.010 |
Why?
|
| Cell Communication | 1 | 1990 | 1660 | 0.010 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2011 | 1883 | 0.010 |
Why?
|
| Head and Neck Neoplasms | 2 | 2007 | 2930 | 0.010 |
Why?
|
| Neuroblastoma | 1 | 2010 | 1266 | 0.010 |
Why?
|
| Hormone Replacement Therapy | 1 | 2007 | 757 | 0.010 |
Why?
|
| Proteoglycans | 1 | 2005 | 809 | 0.010 |
Why?
|
| Reproducibility of Results | 2 | 2012 | 20218 | 0.010 |
Why?
|
| Collagen Type I | 1 | 2005 | 618 | 0.010 |
Why?
|
| Transaminases | 1 | 2002 | 199 | 0.010 |
Why?
|
| Lipopolysaccharides | 1 | 1989 | 2219 | 0.010 |
Why?
|
| Biomedical Research | 2 | 2007 | 3463 | 0.010 |
Why?
|
| Neoplastic Stem Cells | 1 | 1989 | 1351 | 0.010 |
Why?
|
| Risk | 1 | 2013 | 9609 | 0.010 |
Why?
|
| Lymphocytes | 1 | 1989 | 2614 | 0.010 |
Why?
|
| Ecdysone | 1 | 1980 | 19 | 0.010 |
Why?
|
| Melanoma-Specific Antigens | 1 | 2001 | 73 | 0.010 |
Why?
|
| Cell Line | 3 | 2010 | 15597 | 0.010 |
Why?
|
| Lung | 1 | 1999 | 10094 | 0.010 |
Why?
|
| Liver Function Tests | 1 | 2002 | 526 | 0.010 |
Why?
|
| beta Catenin | 1 | 2006 | 1047 | 0.010 |
Why?
|
| Fluorine Radioisotopes | 1 | 2003 | 425 | 0.010 |
Why?
|
| Toxicity Tests | 1 | 2001 | 114 | 0.010 |
Why?
|
| Cross-Cultural Comparison | 1 | 2004 | 638 | 0.010 |
Why?
|
| N-Acetylneuraminic Acid | 1 | 2001 | 175 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2003 | 1683 | 0.010 |
Why?
|
| Zebrafish | 1 | 2011 | 3036 | 0.010 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2010 | 2800 | 0.010 |
Why?
|
| Linear Models | 1 | 2009 | 5884 | 0.010 |
Why?
|
| Monocytes | 1 | 1989 | 2605 | 0.010 |
Why?
|
| Melphalan | 1 | 2001 | 421 | 0.010 |
Why?
|
| Lung Diseases | 1 | 1989 | 1944 | 0.010 |
Why?
|
| Muscle, Skeletal | 1 | 2014 | 4978 | 0.010 |
Why?
|
| Models, Chemical | 1 | 2001 | 610 | 0.010 |
Why?
|
| Fee-for-Service Plans | 1 | 2004 | 713 | 0.010 |
Why?
|
| Cost Savings | 1 | 2004 | 904 | 0.010 |
Why?
|
| Managed Care Programs | 1 | 2004 | 939 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2013 | 9384 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2004 | 2923 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2003 | 1244 | 0.010 |
Why?
|
| RNA Interference | 1 | 2006 | 2830 | 0.010 |
Why?
|
| Prostatic Neoplasms | 1 | 2000 | 11101 | 0.010 |
Why?
|
| Drug Utilization | 1 | 2004 | 1190 | 0.010 |
Why?
|
| Radiopharmaceuticals | 1 | 2007 | 2736 | 0.010 |
Why?
|
| Stem Cell Transplantation | 1 | 2006 | 1596 | 0.010 |
Why?
|
| C-Reactive Protein | 1 | 1989 | 3858 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2001 | 2748 | 0.010 |
Why?
|
| Thiotepa | 1 | 1997 | 66 | 0.010 |
Why?
|
| Child, Preschool | 2 | 2018 | 42665 | 0.010 |
Why?
|
| Nucleic Acid Hybridization | 2 | 1989 | 1305 | 0.010 |
Why?
|
| Erythropoiesis | 1 | 2001 | 691 | 0.010 |
Why?
|
| Temperature | 1 | 2003 | 2234 | 0.010 |
Why?
|
| Palliative Care | 1 | 2012 | 3642 | 0.010 |
Why?
|
| Transplantation, Heterologous | 1 | 2005 | 2392 | 0.010 |
Why?
|
| RNA-Directed DNA Polymerase | 1 | 1997 | 222 | 0.010 |
Why?
|
| RNA-Binding Proteins | 1 | 2005 | 1889 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2005 | 4146 | 0.010 |
Why?
|
| DNA Probes | 1 | 1997 | 542 | 0.010 |
Why?
|
| Phenotype | 1 | 2014 | 16723 | 0.010 |
Why?
|
| Transfection | 1 | 2003 | 5757 | 0.010 |
Why?
|
| Infant | 1 | 2018 | 36534 | 0.010 |
Why?
|
| DNA Primers | 1 | 2000 | 2827 | 0.010 |
Why?
|
| DNA | 1 | 1989 | 7213 | 0.010 |
Why?
|
| Societies, Medical | 1 | 2007 | 3966 | 0.010 |
Why?
|
| Dexamethasone | 1 | 2002 | 1964 | 0.010 |
Why?
|
| Reticulocyte Count | 1 | 1994 | 36 | 0.010 |
Why?
|
| Technetium | 1 | 1994 | 328 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2004 | 6339 | 0.010 |
Why?
|
| Blood Component Transfusion | 1 | 1994 | 141 | 0.010 |
Why?
|
| Etoposide | 1 | 1995 | 640 | 0.010 |
Why?
|
| Trans-Activators | 1 | 2003 | 2857 | 0.010 |
Why?
|
| Hyperplasia | 1 | 1996 | 1151 | 0.010 |
Why?
|
| Genome | 1 | 2000 | 1754 | 0.010 |
Why?
|
| Multiple Myeloma | 1 | 1989 | 5196 | 0.010 |
Why?
|
| Drosophila melanogaster | 1 | 1980 | 1726 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2007 | 14486 | 0.010 |
Why?
|
| Health Expenditures | 1 | 2004 | 2389 | 0.010 |
Why?
|
| Bryostatins | 1 | 1990 | 24 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 1994 | 2000 | 0.010 |
Why?
|
| Mental Disorders | 1 | 1989 | 6875 | 0.010 |
Why?
|
| Fluorouracil | 1 | 1994 | 1652 | 0.010 |
Why?
|
| Macrolides | 1 | 1990 | 204 | 0.010 |
Why?
|
| Receptors, Lymphocyte Homing | 1 | 1989 | 141 | 0.010 |
Why?
|
| L-Selectin | 1 | 1989 | 212 | 0.000 |
Why?
|
| Anaphylaxis | 1 | 1996 | 755 | 0.000 |
Why?
|
| Restriction Mapping | 1 | 1989 | 849 | 0.000 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1989 | 1057 | 0.000 |
Why?
|
| Cryopreservation | 1 | 1993 | 733 | 0.000 |
Why?
|
| Methotrexate | 1 | 1994 | 1721 | 0.000 |
Why?
|
| Granulocytes | 1 | 1989 | 551 | 0.000 |
Why?
|
| Plasmids | 1 | 1989 | 2269 | 0.000 |
Why?
|
| Cell Adhesion Molecules | 1 | 1989 | 1613 | 0.000 |
Why?
|
| Cell Adhesion | 1 | 1989 | 3096 | 0.000 |
Why?
|
| Skin | 1 | 1996 | 4503 | 0.000 |
Why?
|
| Antibodies | 1 | 1990 | 2421 | 0.000 |
Why?
|
| Enzyme Induction | 1 | 1980 | 455 | 0.000 |
Why?
|
| Molecular Weight | 1 | 1980 | 2173 | 0.000 |
Why?
|
| B-Lymphocytes | 1 | 1989 | 4791 | 0.000 |
Why?
|
| Protein Biosynthesis | 1 | 1980 | 2094 | 0.000 |
Why?
|